TREATMENT MANNERS, GLYCEMIC CONTROL, AND C - REACTIVE PROTEIN IN PATIENTS RECEIVING ANTIDIABETIC OR ANTIDIABETIC WITH ANTIHYPERTENSIVE DRUGS IN BASRA
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i11.29588Keywords:
Antidiabetic drugs, Antihypertensive drugs, C-reactive proteinAbstract
Objective: This study aimed at investigating the relationship between treatment manners, glycemic control, and C-reactive protein (CRP) serum level in patients receiving antidiabetic drugs (ADM) alone or ADM with antihypertensive (AHT) drugs in Basra.
Methods: Patients receiving ADM or ADM with AHT drugs, not suffering from complications, were recruited from Al-Mawanee General Hospital in Basra. Socioeconomic characteristics, blood pressure (BP), and treatment plans were recorded. Blood samples were obtained to measure glycated haemoglobin (HbA1c), lipids profile, and high sensitive (hs-CRP).
Results: A total of 26 men and 50 women were involved. Lower mean HbA1c was found in patients receiving ADM with AHT drugs compared with those on ADM drugs only (p=0.0013). Lower mean systolic BP (p<0.0001) and diastolic BP (p=0.0078) were found in patients receiving ADM drugs only compared with those receiving ADM with AHT drugs. Lower mean hs-CRP was found in women receiving ADM with AHT drugs compared with those on ADM drugs only. Treatment manners had no effect on mean hs-CRP in men and women receiving ADM with AHT drugs; however, there was a significant direct correlation of hs-CRP with HbA1c (p=0.002) and triglycerides (p=0.009), but inversely with high-density lipoprotein cholesterol (p=0.011) in women receiving ADM drugs only.
Conclusion: High levels of hs-CRP are associated with poor glycemic control and dyslipidemia, therefore, consequently increased cardiovascular risk. Due to its value as a risk predictor, hs-CRP should be included in routine monitoring of Type-2 diabetic patients.
Downloads
References
King DE, Mainous AG 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003;26:1535-9.
Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a japanese population: Jichi medical school cohort study. Am J Epidemiol 2001;153:1183-90.
Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI, et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19:857-61.
Gayathri B, Vinodhini VM. High sensitive C-reactive protein and its relationship with other cardiovascular risk variables in obese, overweight and healthy individuals. Asian J Pharm Clin Res 2018;11:194-8.
Senghor A, William E. Non-HDL and AIP compared to Hs-CRP in hypertriglyceridemic diabetics-a better cardiovascular risk marker? Asian Pharm Clin Res 2013;6:128-30.
Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966;123:365-78.
Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001;38:189-97.
Prasad K. C-reactive protein and cardiovascular diseases. Int J Angiol 2003;12:1-12.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
Anderson HC, McCarty M. Determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever. Am J Med 1950;8:445-55.
Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84:149-61, ix.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther 2004; 9:203–209.
Zeller JM, Sullivan BL. C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by igG-stimulated monocytes and neutrophils. J Leukoc Biol 1992;52:449-55.
Prasad K, Lee P. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther 2003;8:61-9.
Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999;100:96-102.
Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001;103:1194-7.
American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care 2014;37 Suppl 1:S14-80.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560-72.
Boyle PJ. Diabetes mellitus and macrovascular disease: Mechanisms and mediators. Am J Med 2007;120:S12-7.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014;6:517-30.
Published
How to Cite
Issue
Section
Copyright (c) 2018 Abdullah S Asia, Kadhim N Sheima, Wrewish S Zainab
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
